Aug 8 2006
Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140.
The patent claims include uses of the antimicrobial peptide for the treatment and prevention of bacterial infections.
Dr. Jeffrey Hillman, Oragenics' Chief Scientific Officer and the inventor of the patented MU1140 technology, stated, "This recently issued patent provides additional intellectual property protection for our lead antibiotic compound. MU1140 represents a major new class of antibiotics and one day could become a clinically useful tool against those bacteria that have grown resistant to existing antibiotics." Oragenics plans to complete by the end of this year the preclinical tests necessary to begin a human clinical trial with its promising molecule, MU1140.